Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets (100 mg, 200 mg and 300 mg Three Times Every Two Hours on One Day and q.d. for Another 2 to 3 Days) in Healthy Male and Female Volunteers, a Randomised, Doubleblind, Placebo-controlled Within Dose Groups Phase I Study

NCT02215759 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02215759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02215759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets (100 mg, 200 mg and 300 mg Three Times Every Two Hours on One Day and q.d. for Another 2 to 3 Days) in Healthy Male and Female Volunteers, a Randomised, Doubleblind, Placebo-controlled Within Dose Groups Phase I Study
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
Not reported
Enrollment
34 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy